Home / Share Price Target / Epigral
Epigral Share Price Target 2024, 2025, 2026 to 2039 With Charts
Epigral Limited | |||
 | Symbol: EPIGRAL | ||
| Price: ₹2,057.44 | |||
| Exchange: NSE | |||
| Basic Materials -> Chemicals | |||
Show Table of Contents
Table of Contents
- 1: Epigral Brief Company Overview
- 1.1: Epigral Limited: A Leading Chlor-Alkali Producer
- 1.2: Epigral Financial Performance
- 1.2.1: Is Epigral A Good Buy For Long Term?
- 2: Approach 1: Technical Analysis Paired With Price Action
- 2.1: Epigral Share Price Target For 2024
- 2.1.1: Epigral Share Price Target Table For 2024
- 2.1.2: Summary: Epigral Share Price Prediction For 2024
- 2.2: Epigral Share Price Target For 2025
- 2.2.1: Epigral Share Price Target Table For 2025
- 2.2.2: Summary: Epigral Share Price Prediction For 2025
- 3: Approach 2: Machine Learning By Studying Historical Prices
- 3.1: Epigral Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 3.2: Epigral Share Price Target Table From 2024, 2025, 2026 to 2039
- 4: Epigral Past Performance
Epigral Brief Company Overview
Epigral Limited: A Leading Chlor-Alkali Producer
Epigral Limited, formerly known as Meghmani Finechem Limited, is an established manufacturer and distributor of chlor-alkali and related derivatives in India and globally. Since its inception in 2007, headquartered in Ahmedabad, India, the company has gained a strong reputation in the industry.
Key Products and Services:- Chlorinated polyvinyl chloride (CPVC) resins
- Epichlorohydrin
- Chloromethanes
- Hydrogen peroxide
- Caustic soda, chlorine, and hydrogen
- Caustic potash products
Epigral serves various sectors, including construction, paints and coatings, water treatment, healthcare, and agriculture, among others. Their products find applications in CPVC pipes and fittings, windmills, agrochemicals, pharmaceuticals, and other industries.
Commitment:Epigral Limited is committed to delivering high-quality products and services while adhering to strict safety and environmental standards.
Advertisement
Epigral Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 9,327.39 Crore | Market valuation of Epigral's shares. |
| Revenue (TTM) | 2,125.5 Crore | Total revenue generated by Epigral over the past twelve months. |
| Net Income (TTM) | +250.22 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 21.95% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 11.77% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) | +43.2% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) | +172.5% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio | 76.87 | Company's total debt divided by total shareholder equity. |
| Total Debt | 964.03 Crore | Sum of Epigral's current & long-term financial obligations. |
| Total Cash | 3.18 Crore | Total amount of liquid funds available to Epigral. |
| Beta | -0.19 | Beta is less than 1 indicating that the Epigral's price is less volatile than the market. |
Is Epigral A Good Buy For Long Term?
Epigral's strong recent performance, with a 142.67% return over the past 12 months and a 122.37% YTD return, is certainly eye-catching. However, a closer look reveals some potential red flags. The company's debt level of 964.03 Crore, coupled with a minimal cash balance of 3.18 Crore, suggests a high level of financial risk. While Epigral's profit margin of 11.77% indicates some profitability, the lack of historical data for the past 3 and 5 years makes it difficult to assess its long-term growth potential. Considering these factors, Epigral is a high-risk, high-reward investment and not necessarily a good buy for long-term investors seeking stability.
To predict the Epigral's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Epigral Share Price Target For 2024
The line chart displays the monthly closing prices of Epigral with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Epigral shares in 2024, see the table below.
Advertisement
Epigral Share Price Target Table For 2024
| Epigral's Levels | Value | Reason/Importance |
|---|---|---|
| 2024 Target 3 | 2139.07 (+3.96%) | Custom Fibonacci Extension Lvl 50% |
| 2024 Target 2 | 2109.69 (+2.53%) | Price Action: 06 Nov 2024 Low |
| 2024 Target 1 | 2079.94 (+1.09%) | Price Action: 24 Oct 2024 High |
| Current Price | 2057.44 | Epigral's 1 share price as of Thu 14 Nov 2024 |
| Stop Loss 1 | 2033.42 (-1.17%) | Fibonacci Retracement Level 38.2% |
| Stop Loss 2 | 2012.87 (-2.17%) | Fibonacci Retracement Level 50% |
| Stop Loss 3 | 1990.55 (-3.26%) | Price Action: 23 Oct 2024 Low |
Summary: Epigral Share Price Prediction For 2024
In summary, Epigral has surged by ₹1080.39, achieving a notable +110.58% increase from 1st January 2024 to 14 Nov 2024. Our analysis of Epigral for 2024 predicts an additional rise of 1.09% to 3.96% by the end of 2024 with three potential targets T1: 2079.94, T2: 2109.69, T3: 2139.07. Stop Loss at SL1: 2033.42, SL2: 2012.87, SL3: 1990.55.
Epigral has a 52-week high of ₹2406.75, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹888.09, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Epigral.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Epigral Share Price Target For 2025
The line chart displays the monthly closing prices of Epigral with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Epigral shares in 2025, see the table below.
Advertisement
Epigral Share Price Target Table For 2025
| Epigral's Levels | Value | Reason/Importance |
|---|---|---|
| 2025 Target 3 | 3105.16 (+50.92%) | Price Action: Chart |
| 2025 Target 2 | 3047.26 (+48.1%) | Fibonacci Extension Level 150% |
| 2025 Target 1 | 2987.30 (+45.19%) | Custom Fibonacci Extension Lvl 64.9% |
| Current Price | 2057.44 | Epigral's 1 share price as of Thu 14 Nov 2024 |
| Stop Loss 1 | 1817.94 (-11.65%) | Price Action: Jul 2024 High |
| Stop Loss 2 | 1799.76 (-12.53%) | Price Action: Chart |
| Stop Loss 3 | 1767.36 (-14.1%) | Price Action: Chart |
Summary: Epigral Share Price Prediction For 2025
In summary, Epigral has surged by ₹1080.39, achieving a notable +110.58% increase from 1st January 2024 to 14 Nov 2024. Our analysis of Epigral for 2025 predicts an additional rise of 45.19% to 50.92% by the end of 2025 with three potential targets T1: 2987.30, T2: 3047.26, T3: 3105.16. Stop Loss at SL1: 1817.94, SL2: 1799.76, SL3: 1767.36.
Epigral has a All-Time high of ₹2406.75, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹888.09, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Epigral, we have created a specific page for that check here: Epigral Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Epigral Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
This chart presents a detailed projection of Epigral share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 17.72% over the next 15 years.
For complete year by year Epigral long term share price target from 2024, 2025 to 2039 check the below table.
Epigral Share Price Target Table From 2024, 2025, 2026 to 2039
| Year | Epigral Target | YoY Change % |
|---|---|---|
| 2024 | ₹2,057.44 | [Current Price] |
| 2024 | ₹2,419.5 | 17.59% |
| 2025 | ₹3,972.12 | 64.17% |
| 2026 | ₹5,326.03 | 34.08% |
| 2027 | ₹6,645.54 | 24.77% |
| 2028 | ₹8,100.22 | 21.88% |
| 2029 | ₹9,573.95 | 18.19% |
| 2030 | ₹11,352.74 | 18.57% |
| 2031 | ₹12,541.11 | 10.46% |
| 2032 | ₹13,728.97 | 9.47% |
| 2033 | ₹15,217.04 | 10.83% |
| 2034 | ₹16,728.41 | 9.93% |
| 2035 | ₹18,733.37 | 11.98% |
| 2036 | ₹19,756.18 | 5.45% |
| 2037 | ₹20,812.4 | 5.34% |
| 2038 | ₹22,333.85 | 7.31% |
| 2039 | ₹23,744.96 | 6.31% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Epigral Past Performance
- In 2021, Epigral opening price was ₹630.25
- As of Thu 14 Nov 2024 the price stands at ₹2,057.44.
- This represents a Compound Annual Growth Rate (CAGR) of 34.42%.
- In 3 years, an investment of 10,000 would have become ₹32,644.82.
As we wrap up, we hope you like our study on Epigral share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.
